Orthofix Medical Inc. (OFIX) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

62OpportunityDD: Aug 25, 2026Analyst: 63

paidReference price

USD 8.93 (11/09/2026)

domainMkt cap

$363.95M

pie_chartShares

40.73M

candlestick_chart52W

$8.85-$16.99

trending_downShort interest

5.4%

INFONASDAQHealth Care1600 employeesFounded 1980

Verdict: Favorable Risk/Reward — Post-Earnings Reset

OFIX remains a post-overhang medtech recovery story, but the setup is now cleaner and harsher than in the July version. Q2 2026 confirmed operational progress: revenue grew 4% reported / 5% pro forma constant currency to $210.9M, adjusted EBITDA was $20.1M, Medicare reimbursement for bone growth stimulators was restored, and FY26 guidance was raised to $845–855M revenue and $95–98M adjusted EBITDA. The stock nevertheless reset to $9.79 after earnings, implying roughly 5.9x FY26 EV/EBITDA. The upside case is multiple normalization; the limiting factors are litigation, low GAAP profitability, integration execution and higher net debt after arbitration payments.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-08-25

Orthofix Medical Inc. (OFIX)

Spine, Orthobiologics & Limb Reconstruction · NASDAQ · Lewisville, TX

"Post-Q2 reset with confirmed EBITDA guidance, but litigation and low margin quality still cap the multiple."

CMS reversal removed overhang FY26 EBITDA guide raised Class action pending Q2 margin still 9.6% EV/EBITDA discount persists

Fin. strength

/20 pt

EBITDA/FCF

/15 pt

Debt/Lev.

/15 pt

Stage/BU

/15 pt

Catalysts

/10 pt

Regulatory

/8 pt

R/R

/7 pt

Mgmt

/5 pt

Sector

/3 pt

Compl.

/2 pt

Fair Value Analysis · EV/EBITDA + tangible book cross-check

Fair value base case

USD 15.3

Range: USD 8.50-USD 21.5

Reference price: USD 8.93 (11/09/2026)

Base upside/downside: +71%

Method & sanity check: Primary method is EV/EBITDA. The 8.0x target multiple sits below the peer median of roughly 8.8x because OFIX has lower growth, lower margin quality and unresolved litigation, but above the current ~5.9x trading multiple because CMS reimbursement has been restored and FY26 EBITDA guidance was raised. Implied multiple of FV base: $15.30 × 40.73M shares = $623M equity; plus ~$130M net debt/lease/legal reserve bridge implies about $753M EV, or ~7.8x FY26 adjusted EBITDA, within 3% of the nominal 8.0x. Cross-check DCF using $35M normalized FY27 FCF, 10% WACC and 3% terminal growth gives roughly $14.50/sh. Sensitivity: ±2x EBITDA multiple moves FV by about ±$4.75/sh, so multiple normalization is the main risk. ⚠️ Not investment advice.

Component	Assumption	USD/share
Core Enterprise Value — EV/EBITDA	8.0x × $96.5M FY26 adjusted EBITDA midpoint = $772M EV / 40.73M shares	$18.96
Cash & restricted cash	$104.4M cash and restricted cash at 2026-06-30 / 40.73M shares	+$2.56
Long-term debt	−$221.6M long-term debt at 2026-06-30 / 40.73M shares	−$5.44
Finance lease liability	−$13.0M current and long-term finance lease liability / 40.73M shares	−$0.32
Class action reserve	−$40M base legal reserve for pending securities / derivative litigation / 40.73M shares	−$0.98
Residual integration upside	40% probability × $9.5M incremental EBITDA from SeaSpine/channel savings × 8.0x / 40.73M shares	+$0.75
Equity dilution reserve	−1.5% haircut × $15.5 intrinsic value for SBC dilution through FY27	−$0.23
FV base case (sum)	18.96 + 2.56 − 5.44 − 0.32 − 0.98 + 0.75 − 0.23 = $15.30	$15.30

Bull

$21.50

Probability: 120%

FY26 adjusted EBITDA lands at or above $100M, Q3 confirms H2 acceleration, spine fixation and limb reconstruction keep double-digit constant-currency growth, and the class action settles below $25M. Multiple re-rates toward 10x.

Base

$15.30

Probability: 56%

FY26 lands near the new midpoint of $850M revenue and $96.5M adjusted EBITDA. CMS reimbursement remains stable, but the market waits for Q3/Q4 proof and applies an 8.0x multiple rather than full peer parity.

Bear

$8.50

Probability: 13%

H2 growth misses the revised plan, 2027 MDR headwind weighs on Europe, litigation cash cost exceeds $70M and the stock remains valued near 5.5x EBITDA. Downside revisits the 52-week low area.

Methodology: Method & sanity check: Primary method is EV/EBITDA. The 8.0x target multiple sits below the peer median of roughly 8.8x because OFIX has lower growth, lower margin quality and unresolved litigation, but above the current ~5.9x trading multiple because CMS reimbursement has been restored and FY26 EBITDA guidance was raised. Implied multiple of FV base: $15.30 × 40.73M shares = $623M equity; plus ~$130M net debt/lease/legal reserve bridge implies about $753M EV, or ~7.8x FY26 adjusted EBITDA, within 3% of the nominal 8.0x. Cross-check DCF using $35M normalized FY27 FCF, 10% WACC and 3% terminal growth gives roughly $14.50/sh. Sensitivity: ±2x EBITDA multiple moves FV by about ±$4.75/sh, so multiple normalization is the main risk. ⚠️ Not investment advice. Not investment advice.

This update keeps the same primary valuation framework used in the prior published DD: FY26 adjusted EBITDA × peer-derived EV/EBITDA, then cash, debt and quantifiable legal reserve. The multiple is lowered from 8.5x to 8.0x because the Q2 print raised guidance but still produced a negative stock reaction, only 9.6% adjusted EBITDA margin, and continued legal/integration overhang.

check_circle

✅ Positive catalyst — Q2 guidance raise after CMS restoration

CMS restored the prior fee schedule for non-invasive bone growth stimulators in July 2026, and Orthofix followed with Q2 results that raised FY26 sales guidance by $7M and adjusted EBITDA guidance by $5M versus the May 21 reset. The positive read-through is real, but the market reaction shows investors still want proof of sustained spine channel execution and cash conversion.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

5.4%

2.12M shares short as of 2026-07-31; days-to-cover 7.4. Moderate short percentage, but high days-to-cover because liquidity is thin after the Q2 reset.

🟡 Share dilution (YoY)

+3.6%

40.73M shares outstanding; StockAnalysis shows +3.56% YoY. Increase is mainly routine equity compensation and merger-related stock comp, not a fresh equity raise.

🔴 Buyback

No active buyback program. Cash is prioritized for debt, litigation/arbitration payments and working capital. Repurchases are unlikely until legal reserve visibility improves.

OFIX — 5.4%

Moderate

Days to cover — 7.4

Elevated

Insider activity (last 12M): recent Form 4s include routine equity-settlement transactions and Equibles flags net 90-day insider transactions around −$450K. No single discretionary insider sale above the $500K threshold was identified in the last 12 months. Insider activity is neutral-to-slightly negative, not thesis-breaking.

$Financial Analysis

Revenue FY26E

$850M

~+5% pf CC YoY

Adj EBITDA FY26E

$96.5M

11.3% margin, expanding

Net cash / (debt)

−$130M

$104.4M cash − $234.6M debt/leases

Q2 adj EBITDA

$20.1M

9.6% margin, −70 bps YoY

Metric ($M)	FY24	FY25	FY26E	FY27E
Net revenue	760	822	850 (guide midpoint)	895
Growth YoY (pf CC)	+3.5%	+5.9%	~+5.0%	+5.0%
Gross margin %	66.8%	68.2%	71.2%	71.5%
Adj EBITDA	72	82	96.5	108
Adj EBITDA margin %	9.5%	10.2%	11.3%	11.9%
Net income	−82	−55	−22	+15
Free cash flow	−30	−12	+5 (ex legal)	+35
Cash & restricted cash (period end)	90	85	104	125
Total debt and finance leases	140	177	235	215

Quarterly progression — last 4 quarters
Quarter	Revenue ($M)	YoY pf CC	Adj EBITDA ($M)	EBITDA margin	Cash ($M)
Q2 25	203.1	N/D	20.6	10.3%	N/D
Q3 25	197.8	+5.4%	17.2	8.7%	81
Q4 25	218.5	+6.1%	32.4	14.8%	78
Q1 26	196.7	+3.0%	9.7	4.9%	120.9
Q2 26	210.9	+4.7%	20.1	9.6%	104.4

FY26 revenue guidance ($845M-$855M)

48% H1 done

FY26 EBITDA guidance ($95M-$98M)

31% H1 done

Current EV/EBITDA vs 8.0x FV multiple

5.9x / 8.0x

account_tree

Business & Segment Mix

Post-SeaSpine merger footprint (closed Jan 2023)

Orthofix operates three global segments post-merger: (1) Global Spine Fixation, including spine fixation hardware; (2) Therapeutic Solutions, including bone growth stimulation devices; and (3) Global Limb Reconstruction, focused on deformity correction, limb lengthening and complex fracture management. Q2 2026 showed double-digit constant-currency growth in Spine Fixation and Global Limb Reconstruction, while Therapeutic Solutions still grew 3% despite the temporary Medicare reimbursement headwind. M6 discontinued product lines are excluded from pro forma comparisons.

Global Spine Fixation ~$395M FY26E (46% rev) 🟢 growing Spine fixation, biologics and enabling technologies. Q2 showed double-digit constant-currency growth in Spine Fixation, but smaller U.S. distributor cleanup remains a watch item. Therapeutic Solutions (Biostim) ~$258M FY26E (30% rev) 🟡 CMS reversal recovery Non-invasive bone growth stimulators. Q2 sales were $64.2M, +2.5% YoY, despite part-quarter reimbursement disruption. Key test is H2 volume normalization after CMS restoration. Global Limb Reconstruction ~$150M FY26E (18% rev) 🟢 steady grower External fixation, deformity correction, limb lengthening and complex fracture management. Q2 sales were $37.7M, +13.2% reported and +11.0% constant currency, the cleanest growth asset in the portfolio.

gavel

Risk Grid

Securities / derivative litigation

High

Exchange Act claims were dismissed without prejudice in March 2026, but Securities Act claims survived and plaintiffs filed a second amended complaint on April 8, 2026. Base valuation reserves $40M; a materially larger settlement would erode cash and delay capital return.

Reimbursement risk (recurring)

Medium

CMS reversed May 21 cut on July 1; risk remains that future coding/fee-schedule changes could reappear. Biostim segment ~30% of revenue is most exposed. Payer mix diversification is a slow-moving defense.

Post-merger integration overhang

Medium

SeaSpine cultural/HR issues drove CEO/CFO/CLO terminations Sep 2023. New management team in place ~2.5 years; some sales channel disruption persisted into Q1 26 spine numbers.

Leverage and liquidity

Medium

Cash and restricted cash fell to $104.4M at Q2, while long-term debt plus finance leases were about $234.6M. Net leverage remains manageable versus FY26 EBITDA guidance, but less comfortable than the July snapshot.

Peer discount could persist

Medium

OFIX trades near 5.9x FY26 EBITDA versus a medtech peer median around 8–9x. The discount is partly deserved because growth is slower, margins are lower and legal overhang remains unresolved.

Q2 evidence improved, but not enough

Positive

Q2 revenue and EBITDA beat the May reset and guidance increased. The negative stock reaction says investors are still penalizing the quality of earnings and waiting for H2 cash generation.

Guidance raise = credibility

Positive

Management raised FY26 sales to $845–855M and adjusted EBITDA to $95–98M after CMS reimbursement was restored. That supports the base case if Q3 confirms sustained operating discipline.

Insider activity

Moderate

Recent insider data is mixed: routine Form 4 transactions and roughly −$450K net 90-day activity were flagged, but no single discretionary insider sale above $500K was identified. Signal is neutral rather than supportive.

Strengths

Diversified 3-segment orthopedic platform post-SeaSpine merger

$104.4M cash and restricted cash at Q2 2026

Limb Reconstruction is a stable, high-margin (~65% GM) grower

Q2 2026 revenue +4.7% pro forma constant currency despite temporary CMS headwind

Weaknesses

Q2 adjusted EBITDA margin of 9.6% still below stronger device peers

Class action from 2023 governance failures still unresolved

Spine channel disruption persisted into Q1 26 numbers

55% of assets are goodwill from SeaSpine merger — thin tangible book

Opportunities

CMS restoration plus raised FY26 guidance support H2 2026 recovery

Peer-multiple gap: ~5.9x current vs 8.0x base FV multiple

EMEA/LATAM expansion for Limb Reconstruction

M&A optionality on tuck-in biologics assets (cash on hand)

Threats

Future CMS/coding changes on biostim reimbursement (recurring)

Class action settlement above $70M erodes cash floor

Larger peers (ATEC, ZBH) accelerate spine share loss

Hospital capex slowdown weighs on capital-equipment sales

🐂 Bull thesis (20%)

Q3 and Q4 confirm H2 acceleration after the CMS restoration

FY26 lands at top of guide ($855M revenue, $98M EBITDA); FY27 sees $105M+

Multiple re-rates to 10x on peer catch-up as legal overhang fades

Class action settles <$25M; buyback resumed by H2 27

⚖️ Base case (45%)

FY26 lands near guide midpoint ($850M revenue, $96.5M EBITDA)

Multiple re-rates only partially to 8.0x, below peer median

Class action settles ~$40M in H2 27; leverage stays <1.5x

H2 execution confirms Q2 was progress, not a one-quarter bounce — FV $15.30 (+56%)

🐻 Bear case (35%)

H2 EBITDA misses despite the Q2 guidance raise

FY26 EBITDA trends toward the low end of guide or below

Class action settlement $70M+ erodes cash cushion

Multiple stays around 5.5x; FV $8.50, near the 52-week low area

{ "verdict_label": {"it": "Giudizio: Risk/Reward Favorevole — Reset Post-Q2", "en": "Verdict: Favorable Risk/Reward — Post-Q2 Reset"}, "verdict_text": {"it": "OFIX ha confermato progresso operativo nel Q2 2026, ma il titolo e' sceso a $9,79. FV base $15,30: upside alto, con rischio legale e margini ancora bassi.", "en": "OFIX confirmed operational progress in Q2 2026, but the stock reset to $9.79. Base FV is $15.30: high upside, with legal risk and still-low margins."}, "bull_points": [ {"it": "Q2 2026: revenue $210,9M, EBITDA adj. $20,1M e guidance FY26 EBITDA alzata.", "en": "Q2 2026: $210.9M revenue, $20.1M adjusted EBITDA and FY26 EBITDA guidance raised."}, {"it": "Ripristino CMS riduce il rischio immediato sul business bone growth stimulation.", "en": "CMS restoration reduces the immediate risk around the bone growth stimulation business."}, {"it": "Il titolo tratta a circa 5,9x EBITDA FY26 vs FV base a 8,0x.", "en": "The stock trades around 5.9x FY26 EBITDA versus an 8.0x base-case FV multiple."} ], "bear_points": [ {"it": "Contenzioso SeaSpine/Orthofix ancora aperto: riserva base $40M.", "en": "SeaSpine/Orthofix litigation remains open: $40M base reserve."}, {"it": "Margine EBITDA Q2 solo 9,6%, ancora sotto i migliori peer medtech.", "en": "Q2 EBITDA margin was only 9.6%, still below stronger medtech peers."}, {"it": "Net debt/lease bridge salito a circa $130M dopo pagamenti arbitrali.", "en": "Net debt/lease bridge rose to roughly $130M after arbitration payments."} ], "risks": [ {"it": "Se Q3 non conferma crescita e margine, il re-rating resta bloccato.", "en": "If Q3 fails to confirm growth and margin recovery, the re-rating remains blocked."}, {"it": "Settlement class action >$70M eroderebbe la cassa e il fair value.", "en": "A class-action settlement above $70M would erode cash and fair value."}, {"it": "Nuovi tagli CMS su biostim restano un rischio ricorrente.", "en": "Future CMS cuts on biostim remain a recurring risk."} ] }

Sources & Disclaimer

Sources: Orthofix Q2 2026 press release and SEC Exhibit 99.1 (August 5, 2026); SEC Q2 2026 Form 10-Q; CMS July 2026 DMEPOS fee schedule update on non-invasive bone growth stimulators; StockAnalysis and Investing.com market data; MarketBeat and Trefis short-interest data; StockAnalysis analyst forecast table updated August 2026; Cohen Milstein and Justia litigation materials for In re Orthofix Medical Inc. Securities Litigation; Equibles insider/ownership summary; prior local DD file OFIX_20260729_1015_ASIM_DISLOCATION.html for methodology continuity. Market data — last verified close 2026-08-24: OFIX $9.79; market cap ~$399M; enterprise value ~$566M; 52W range $8.85–$16.99; shares outstanding 40.73M. Short interest: 2.12M shares, 5.4% of shares, 7.4 days-to-cover as of 2026-07-31. Analyst average price target: $13, with latest target updates dated 2026-08-05 to 2026-08-10. ⚠️ Not investment advice. This document is for informational purposes only and does not constitute financial or investment advice.